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Abstract Our interesting case deals with the clinical and
morphological aspects of a chronic neutrophilic leukemia
and the critical evaluation of differential diagnosis of
leukemoid reaction in bone marrow biopsies.
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Introduction
Our interesting case deals with the clinical and morpholog-
ical aspects of a chronic neutrophilic leukemia (CNL) and
the critical evaluation of differential diagnosis of leukemoid
reaction in bone marrow biopsies.
Case
An 81-year-old male patient was admitted to our hospital
suffering from diabetes mellitus, chronic coronary heart
disease, and Coombs-positive hemolysis as well as a
suspicious war wound associated with recurrent osteomy-
elitis of the left femur. The indication for a bone marrow
biopsy was a prolonged neutrophilic leukocytosis in
combination with anemia and enhanced erythrocyte sedi-
mentation rate (see Table 1). In 2004, the first bone marrow
biopsies (without bone marrow smear) were sent from an
external clinic to our institute. The bone marrow routine
histology (see Fig. 1) displayed a prominent hyperplasia of
hematopoiesis with striking dominance of granulopoiesis
and hyoplasia of erythropoiesis without signs of dysplasia.
The megakaryocytopoiesis showed normal number without
significant signs of dysplasia. No relevant number of blasts
or immature granulocytes was found. The age-related
adipose tissue was significantly reduced and enhanced iron
deposits in macrophages were observed (see Fig. 1). At this
time a bone marrow smear was not carried out as these
morphological findings were interpreted as reactive in
circumstances of the clinically communicated osteomyelitis.
An additional outpatient laboratory analysis was per-
formed in the year 2005 confirming persisting leukocytosis
(see Table 1).
Because leukocytosis continued further, the patient was
admitted to our clinic in 2006. At the admission, enhanced
white blood cell count of 30 g/l was observed rising up
from 30 to 63.12 g/l (the latter at the day of death) during
the whole period of hospitalisation (from 9 September 2006
to 2 October 2006). Additionally, the relative percentage of
band and segmented neutrophilic granulocytes was elevated
at admission without evident monocytosis or immature cells
(such as promyelocytes, myelocytes, or metamyelocytes),
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blood smear was performed at the same time as the
respiratory infection was detected being associated with a
left shift (see Table 1). Other parameters of peripheral blood
analysis were: Hgb, 8.2 g/dl; Hkt, 28.0%; RBC, 2.6 T/l;
MCV, 106.1 fl; MCH, 31.1 pg; and PLT, 45 g/l.
Interestingly, compared to the earlier clinical stays, C-
reactive protein (CRP) was continuously low and vitamin
B12 was strongly elevated during the last stay (see Table 1).
Most of the other laboratory findings were associated
with the known diseases of the patient or elevated pre-
mortem, especially the kidney function ((electrolytes:
chloride, 96 mmol/l; sodium, 136 mmol/l; potassium,
4.3 mmol/l; calcium, 1.82 mmol/l) (proteins: total protein/
serum, 6.7 g/dl) (liver function: GOT, 68 U/l; GPT, 22 U/l;
gGT, 92 U/l; cholinesterase, 4.2 U/ml; alkaline phosphatase,
125 U/l) (kidney function: creatinine up to 3.7 mg/dl; blood
urea nitrogen up to 218 mg/dl)). Additionally, clinical and
physical investigation revealed hepato- and splenomegaly as
well as enlarged lymph nodes. Osteomyelitis or other foci of
local infections as well as a solid tumor were excluded by
radiology or other physical methods (especially with 772
MBq Tc-99 m scintigraphy).
New bone marrow samples (bone marrow biopsy and
smear as well as a peripheral blood smear) were taken 1 day
after admission to our hospital (10 September 2006). In
comparison to the first biopsies in 2004, the bone marrow
histology showed the same morphological features (see
Fig. 1): (a) pronounced hypercellularity with severe reduc-
tion of the age-related adipose tissue, (b) marked granulo-
cytic hyperplasia, normal differentiation of erythro- and
megakaryocytopoiesis with slightly reduced number, no
blast transformation (c) 1+ reticulin fibrosis, and (d) en-
hanced iron deposits in the macrophages. We performed a
reverse transcriptase–polymerase chain reaction (RT–PCR)
molecular analysis to exclude a classical chronic myelo-
proliferative disease, which was negative for the major and
minor breakpoint cluster region p210 and p190 of the bcr
gene and jak-2 (somatic mutation Val617Phe) gene muta-
tion, respectively [1, 2]. In accordance with the bone
marrow histology the bone marrow smear showed pro-
nounced hypercellularity with dominance of segmented
granulocytes and without blasts. Cytological signs of hema-
topoetic dysplasia were not evident. Mainly, segmented or
band neutrophilic granulocytes dominated in the peripheral
blood smear without enhanced immature cells (promyelo-
cytes, myelocytes or metamyelocytes). Overall, we favored
the diagnosis of a chronic neutrophilic leukemia in contrast
to the diagnosis in 2004 of a leukemoid reaction. A liver
biopsy showed MPOX-positive granulopoiesis intralobular
and in the portal tract as well as less frequent erythropoesis
and CD61-positive megakaryocytopoiesis indicating ad-
vanced extramedullary hematopoiesis.
The patient died due to pulmonary aspergillosis, which
was detected 5 days before death by radiological inves-
tigations. Autopsy findings confirmed the previous clinical
and bioptic findings with extreme hyperplastic and packed
hematopoiesis with dominance of the granulopoiesis and
extraordinary extramedullary hematopoesis involving liver
(1890 g) and spleen (980 g) as well as lymph nodes (see
Fig. 1g,h). Other hematological disorders such as acute
myelogeneous leukemia as well as Hodgkin’s or Non-
Hodgkin’s lymphoma were excluded by histology and
immunohistochemistry postmortem (CD3, CD10, CD20,
TDT, MPOX, CD34, CD61, Glycophorin, c-kit, CD68).
Additionally, no acute or chronic osteomyelitis was found
in the left femur by autopsy.
Discussion
Based on these findings, we proposed the diagnosis of a
myeloproliferative disease and especially the rare form of a
chronic neutrophilic leukemia. Comparing our findings
with the proposed WHO diagnostic criteria for chronic neu-
trophilic leukemia [3] there are many arguments supporting
the favored diagnosis of CNL: (a) the peripheral blood
leukocytes of the patient showed a prolonged leukocytosis
with counts over >=25g/l. (b) Every bone marrow biopsy
revealed hypercellularity with typical aspects of CNL with
segmented neutrophils and bands >80% of white cells,
immature granulocytes <10% of white cells as well as
myeloblasts <1% in the peripheral blood differential.( c )
Molecular analysis detected no Philadelphia chromosome or
Table 1 Summary of the documented clinical and relevant laboratory
findings during the last clinical stays
Normal range 2004 2005 2006
Hepatosplenomegaly
a NA NA Yes
Vit-B12 (pg/ml) >170 310 313 >2000
CRP [mg/dl]
b <0.6 1.5 1.5 2.1
Leukocytes [g/l]
b 4–10 14.0 11.8 30.7 (33.9
c)
Promyelocytes [%]
b <1 0 NA 2 (2
c)
Myelocytes [%]
b <1 1 NA 3 (5
c)
Metamyelocyes [%]
b <1 1 NA 1 (7
c)
Band granulocytes [%]
b <3 10 NA 10 (9
c)
Neutrophilic
granulocytes [%]
b
50–70 59 70.8 65 (57
c)
Lymphocytes [%]
b 20–40 14 15.3 4 (5
c)
Monocytes [%]
b 1–11 4 NA 5 (15
c)
Eosinophils [%]
b <4 11 NA 9 (0
c)
Basophils [%]
b <1 0 NA 1 (0
c)
NA Not available
aBy clinical or physical investigation
bAt admission
c5 days before death
24 J Hematopathol (2008) 1:23–27BCR/ABL fusion. Additional cytogenetic analysis was not
carried out to identify clonality of the granulocytic prolifer-
ation or chromosomal alterations which could be observed in
about 37% of cases with CNL [4]. (d) Morphological as well
as immunohistochemical analyses of the bone marrow
smears or biopsies as well as peripheral blood differential
excluded the evidence of another myeloproliferative disease
(PV, ET, CIMF) or of a myelodysplastic syndrome or
myelodysplastic/myeloproliferative disorder.( e )Hepatosple-
nomegaly was proofed by clinical and autoptic findings. (f)
Finally, the WHO criteria for CNL included that no
identifiable cause of physiologic neutrophilia was evident.
Fig. 1 Consecutive bone marrow biopsies (a–e) and smear (f)t a k e n
from 2004 (a and b)t o2 0 0 6( c–f) showing imitating “reactive features”
of the hematopoesis in the first biopsies (a–b) and giving evidence for
the diagnosis of a chronic neutrophilic leukemia later (c–f): striking
hematopoetic hypercellularity with reduced age-dependent adipose
tissue, dominance of the granulopoesis in contrast to normal erythro-
and megakaryocytopoesis as well as no blast transformation. Postmor-
tem analysis revealed extraordinary extramedullary hematopoesis
involving liver (g) and spleen (h)( a ×50 (NASD reaction and b ×400
(NASD reaction, inset BB ×400) as well as c ×12.5 (HE), d ×200
(NASD reaction), e ×400 (NASD reaction) and f ×400 (May-
Grunwald-Giemsa), g and h ×400 (HE) and ×50 (MPOX immunohis-
tochemistry) insets,r e s p e c t i v e l y )
J Hematopathol (2008) 1:23–27 25Anamnesis of our presented patient revealed a chronic
osteomyelitis which could be excluded by radiological and
autoptic investigations. The pulmonary aspergillosis was
evident in the prefinal phase of the patient in circumstances
of progressive extramedullary hematopoesis possibly with
functional granulopoesis impairment.
Overall, CNL is a really rare disease. Applying
correctly the WHO criteria to cases with suspicious
CNL, many of these cases did not meet these criteria
[5]. Elliot et. al. presented overall 40 cases being in line
with these criteria of CNL [6]: in short, these patients were
predominantly older and male (17 female, 23 male; age
(years), 66.5 [15–86]) showed a leukocytosis without
immature granulocytes or blasts (Hgb (g/dl), 11.2 (7–
16.7); PLT (g/l), 136 (7–476); white blood count (g/l), 39.1
(11.3–125.7); polymorphonuclear neutrophils (%), 87 (68–
98.5); immature neutrophils, 2 (0–11); Blast (%), 0),
splenomegaly (28/40), cytogenetic abnormalities (8/40
(initial), +5/40 (during follow-up) (32.5%)) and a short
survival time (months: 23.5 (1–94)) as well as different
causes of death (intracranial hemorrhage (n=9), progressive
disease (n=5), blast transformation (n=4), infection (n=1),
regimen-related toxicity post-transplantation (n=1)).
The major and sometimes very difficult differential
diagnosis of CNL is the leukemoid reaction with leuko-
cyte count greater than 50.00 g/l and significant increase
in mature neutrophils with a marked left shift. Causes of
leukemoid reaction are very heterogeneous ranging from
infections, malignancies, drugs, intoxications and severe
hemorrhage and acute hemolysis to rare conditions such as
alcoholic steatohepatitis indicating that really nothing
could be excluded as being responsible for a leukemoid
reaction [7]. In our case, the clinical diagnosis of
osteomyelitis could be excluded by autopsy and the
progressive pulmonary aspergillosis was clinically/radiolog-
ically evident only 5 days before death.
To differentiate between leukemoid reaction and CNL as
well as chronic myelogenous leukemia (CML) are a mix-
ture of blood, bone marrow and molecular biological inves-
tigation has to be applied as follows: (a) peripheral blood
and bone marrow, (b) leukocyte alkaline phosphatase, (c)
vitamin B12, (d) cytogenetics, (e) immunophenotyping, (f)
serum-granulocyte-colony-stimulating factor (G-CSF), and
(g) clonality techniques.
Peripheral blood and bone marrow analyses showed a
left shift of granulopoiesis with myelocytes and metamye-
locytes in case of leukemoid reaction in contrast to a
marked neutrophilia without immature cells as well as
myelocytes and metamyelocytes in cases of CNL [8]. In
contrast, CML displays more immature cells as well as
eosinophils and basophils [9]. Additionally, toxic granula-
tions, Doehle bodies, and cytoplasmatic vacuoles could be
found in neutrophils of patients with leukemoid reaction
[8]. Leukocyte alkaline phosphatase score is higher in cases
of leukemoid reaction and CNL than in cases of CML [4,
10]. Vitamin B12 levels are higher in CNL and CML, but
can not be used to differentiate from a leukemoid reaction
[7]. Cytogenetics analyses are negative in cases of
leukemoid reaction, whereas in 37% of CNL cases abnor-
malities can be found (especially in chromosome 20) [4].
Interestingly, approximately 20% of these patients with
CNL had chromosomal abnormalities already at baseline or
presentation, while about 10–15% developed over time [6].
The hallmark of CML is the presence of Philadelphia 1
chromosome in the karyotype or the detection of t(9;22)
translocation, which is not present in 10% of atypical
myeloproliferative disorders [11]. Additionally, Philadelphia
chromosome negative CML with p230 Bcr-abl gene product
displays distinct neutrophilia [9]. Immunophenotyping is
useful to exclude blast transformation and therefore indicates
a true malignant hematological disorder. Serum-G-CSF is
low in cases of CNL and CML in contrast to higher levels in
cases of a leukemoid reaction which is normally not
available in a standard laboratory [7]. Finally clonality
techniques such as the progenitor cell assays [12], the X-
inactivation patterns [13] and reduced susceptibility of
malignant neutrophils to apoptosis [14] are useful to identify
clonality in cases of CNL/CML and not of leukemoid
reaction which is reserved for specialized laboratories.
Additionally, microbiological as well as physical examina-
tions such as CT or NMR could be helpful to detect a focus
of infection or a malignant tumor.
Relating to our case, we were not able to carry out
investigations such as leukocyte alkaline phosphatase, cyto-
genetics, serum-G-CSF and clonality techniques. Never-
theless, the rest of the above mentioned analyses give
evidence for a chronic neutrophilic leukemia: vitamin B12
was highly elevated and a marked neutrophilia without
dysplasia and immature cells was seen in peripheral blood
and bone marrow specimen. Immunohistochemistry could
exclude a blast transformation. Additionally, the major and
minor breakpoint cluster region p210 and p190 of the bcr
gene and jak-2 (somatic mutation Val617Phe) as well as
blast excess were excluded by RT-PCR and immunohisto-
chemistry. Although a neutrophilic variant of a CML with
p230 Bcr-abl gene product could not be excluded by our
molecular analysis, the presented morphological phenotype
of our case is not constituent with an atypical CML or a Ph-
1/bcr+-CML but with the rare diagnosis CNL [9].
Taken together not as a single criterion, but as a
sometimes time-dependent consecutive combination of
these “standard laboratory” criteria (such as bone marrow
smear and biopsy as well as peripheral blood analysis) can
be helpful in the diagnostic challenge for discriminating
between reactive hematopoiesis and rare chronic neutro-
philic leukemia.
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